Olgica Laban Grant, MD
Neurology · White Plains, NYNPI 1639158462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by UCB, Inc. at 46.1% of the total. Reporting peaked in 2023 at $230 and has fallen 93.3% since, to $15 in 2025. That places this record below the midpoint for neurology clinicians in NY, where the typical reported total is $913.
Across 20 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$196
- Jazz Pharmaceuticals Inc.$73
- Aquestive Therapeutics, Inc.$69
- Sumitomo Pharma America, Inc.$24
- Greenwich Biosciences, Inc.$19
- Livanova USA, Inc.$17
- plus $27 from 2 others
What the payments were for
- Food & beverage$425100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 6 | $196 |
| Jazz Pharmaceuticals Inc. | 4 | $73 |
| Aquestive Therapeutics, Inc. | 3 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $24 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $15 |
| Aucta Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$425 in reported general payments places this provider in the 40th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 21 | $166,956 |
| XcopriCenobamate | 118 | $162,234 |
| AptiomEslicarbazepine Acetate | 84 | $133,518 |
| VimpatLacosamide | 113 | $121,035 |
| BriviactBrivaracetam | 82 | $113,199 |
| ZonegranZonisamide | 24 | $71,100 |
| Rufinamide | 39 | $69,489 |
| Trokendi XrTopiramate | 49 | $48,882 |
| Lamictal XrLamotrigine | 14 | $47,202 |
| LamictalLamotrigine | 46 | $47,198 |
| Lacosamide | 232 | $41,534 |
| Lamotrigine ErLamotrigine | 146 | $36,104 |
| Oxtellar XrOxcarbazepine | 27 | $35,536 |
| Keppra XrLevetiracetam | 28 | $35,491 |
| KeppraLevetiracetam | 13 | $33,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat, Briviact, Nayzilam | $196 | $257,427218 claims |
| SK Life Science, Inc.Xcopri | $15 | $162,234118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,623 neurology providers in New York.
Other neurology in White Plains
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.